UK Markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.32-0.17 (-1.36%)
At close: 04:00PM EST
12.15 -0.17 (-1.38%)
After hours: 05:04PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 313.97
52-week low 37.40
50-day moving average 310.14
200-day moving average 310.22

Share statistics

Avg vol (3-month) 3345.03k
Avg vol (10-day) 3253.56k
Shares outstanding 553.46M
Implied shares outstanding 6N/A
Float 845.12M
% held by insiders 116.18%
% held by institutions 167.91%
Shares short (13 Oct 2022) 46.38M
Short ratio (13 Oct 2022) 416.76
Short % of float (13 Oct 2022) 416.81%
Short % of shares outstanding (13 Oct 2022) 411.87%
Shares short (prior month 14 Sept 2022) 47.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 315 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -135.72%
Operating margin (ttm)-137.11%

Management effectiveness

Return on assets (ttm)-18.70%
Return on equity (ttm)-32.53%

Income statement

Revenue (ttm)48.89M
Revenue per share (ttm)0.93
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-59.67M
EBITDA -66.78M
Net income avi to common (ttm)-66.35M
Diluted EPS (ttm)0.18
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)157.51M
Total cash per share (mrq)2.93
Total debt (mrq)2.82M
Total debt/equity (mrq)1.38
Current ratio (mrq)8.32
Book value per share (mrq)4.99

Cash flow statement

Operating cash flow (ttm)-45.39M
Levered free cash flow (ttm)-20.34M